Liver injury prompts agomelatine label update
This article was originally published in Scrip
Executive Summary
Doctors have been warned of "several serious cases of hepatotoxicity" associated with Servier's antidepressant Valdoxan/Thymanax (agomelatine), including six reports of hepatic failure, since the drug was launched in Europe in 2009, for major depressive disorders in adults.